Globally known professor and dermatologist joins LEO Pharma
9.10.2023 10:00:00 CEST | LEO Pharma | Pressemeddelelse
Ahead of EADV, LEO Pharma announces that Professor Alexander Egeberg, a board-certified dermatologist, and top key opinion leader, will join the company as Head of Global Medical Affairs.

GLOBAL RELEASE – NOT FOR UK USE – NOT INTENDED FOR UK MEDIA
BALLERUP, Denmark, October 9, 2023 – LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs. The announcement happens ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress.
Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology. He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background. Having authored over 300 international scientific publications, he is an expert in inflammatory skin diseases with extensive experience in epidemiology, real-world evidence, translational medicine, and clinical trials. In addition Alexander has through his work in Medial Affairs at Pfizer and as a consultant for additional global pharma companies built a solid understanding of corporate pharma. The appointment of Professor Egeberg cements LEO Pharma’s commitment to medical dermatology and to integrate the clinicians and patients voices at the core of the organization.
Professor Alexander Egeberg comments:
“I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs. Medical dermatology is a rapidly evolving field, yet there are still many diseases with few or no good treatment options. LEO Pharma has a proud 115-year legacy in dermatology, but their ambition and transformative journey is beyond exhilarating. I look very much forward to applying my experience and perspective to support the company’s commitment to advancing care for patients with dermatological diseases.”
Becki Morison, EVP Global Product Strategy and International Operations with LEO Pharma comments:
“I am very pleased that such a strong, international profile in the dermatology space has decided to join LEO Pharma. With him on board we are adding extensive clinical experience and strong understanding of patients’ needs into our medical affairs work. Alexander will certainly strengthen a dermatologic mindset across our organization and ensure that we always put patient needs at the core as we continue to make a fundamental difference for those who need us most in medical dermatology. I am thrilled to welcoming Alexander to our team and looking forward to seeing his contributions to Global Medical Affairs and to our organization.”
Professor Egeberg will start in his new role January 1, 2024, reporting to Becki Morison. He will remain affiliated with the Department of Dermatology at Bispebjerg Hospital, and the University of Copenhagen to ensure that the patients’ needs, and the voice of the medical community remains deeply embedded in the core values and practices of the company going forward.
Kontakter
Karen Frost
Tlf:+45 3166 1567kasfr@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma delivers 10% revenue growth at CER and strengthens late-stage pipeline18.8.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2026 – In H1 2026, LEO Pharma delivered strong revenue growth, driven by the dermatology portfolio, with an improved gross margin alongside significantly increased investments in commercial and innovation activities. In August, LEO Pharma agreed to acquire the global rights for dersimelagon, an investigational first-in-class oral therapy with potential launch in 2027. Together with the acquisition of Replay, announced in April 2026, the agreement further strengthens LEO Pharma’s pipeline in rare genetic skin diseases. Financial highlights LEO Pharma’s revenue increased by 7% to DKK 7,257 million, and by 10% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) and Rest of World (10% at CER), while sales in Europe (0% at CER) were broadly stable compared to H1 2025. Revenue from the Dermatology portfolio grew by 12% (CER), driven by the strategic brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had a revenu
LEO Pharma further strengthens late-stage pipeline with the acquisition of dersimelagon18.8.2026 08:58:00 CEST | Pressemeddelelse
Acquisition adds dersimelagon to LEO Pharma’s rare dermatology pipeline, an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) that has completed Phase 3 development and for which a New Drug Application (NDA) has been submitted to U.S. Food and Drug Administration (FDA) for review in June 2026.1 Leverages LEO Pharma's six decades of dermatology expertise to advance innovation for patients with rare skin diseases through the addition of this oral late-stage asset, building on LEO Pharma’s recent acquisition of Replay and partnership with Boehringer Ingelheim for Spevigo® (spesolimab). EPP and XLP are rare, devastating lifelong genetic disorders that cause severe sunlight-induced skin pain, as well as rash, swelling, redness, burning sensations and, in some cases, liver damage.2,3 Under the terms of the agreement, LEO Pharma will acquire worldwide rights to dersimelagon from Tanabe Pharma for up
LEO Pharma elects Henriette Mersebach to the Board of Directors14.8.2026 09:00:00 CEST | Pressemeddelelse
Henriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the Board
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum